J G Maring A B P van Kuilenburg J Haasjes H Piersma H J M Groen D R A Uges A H Van Gennip E G E De Vries
10.1038/sj.bjc.6600208
Br J Cancer
2002 Apr 8;86(7):1028-33.
CC BY
https://pubmed.ncbi.nlm.nih.gov/11953843/
Antimetabolites, Antineoplastic / adverse effects Antimetabolites, Antineoplastic / pharmacokinetics DNA, Neoplasm / genetics Fluorouracil / adverse effects Fluorouracil / pharmacokinetics Oxidoreductases / pharmacology Point Mutation
Antimetabolites, Antineoplastic / adverse effects Antimetabolites, Antineoplastic / pharmacokinetics DNA, Neoplasm / genetics Fluorouracil / adverse effects Fluorouracil / pharmacokinetics Oxidoreductases / pharmacology Point Mutation Case Reports Aged Alleles Chromatography, High Pressure Liquid Colorectal Neoplasms / drug therapy Dihydrouracil Dehydrogenase (NADP) Female Humans Leucovorin / administration & dosage Male Middle Aged Oxidoreductases / genetics Polymerase Chain Reaction Sequence Analysis, DNA Antimetabolites, Antineoplastic DNA, Neoplasm Oxidoreductases Dihydrouracil Dehydrogenase (NADP) Leucovorin Fluorouracil
PMC2364178
11953843
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
2002